Latest Articles

Publication Date
VIDEO: Puxitatug samrotecan shows promise for patients with recurrent endometrial cancer - Healio

VIDEO: Puxitatug samrotecan shows promise for patients with recurrent endometrial cancer Healio

Published: May 14, 2025, 8:04 p.m.
Dostarlimab/Chemo Earns Expanded Canadian Approval in Primary Advanced, First Recurrent Endometrial Cancer - OncLive

Dostarlimab/Chemo Earns Expanded Canadian Approval in Primary Advanced, First Recurrent Endometrial Cancer OncLive

Published: April 18, 2025, 3:54 p.m.
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - BioSpace

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 18, 2025, 5:25 a.m.
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - The Malaysian Reserve

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 18, 2025, 12:16 a.m.
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - Yahoo Finance

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 17, 2025, 5:15 p.m.
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - Newswire.ca

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 17, 2025, 5:15 p.m.
Real-World Use of ICI in Advanced or Recurrent Endometrial Cancer - OncLive

Real-World Use of ICI in Advanced or Recurrent Endometrial Cancer OncLive

Published: April 14, 2025, 2:41 p.m.
Comprehensive individualised interventions may improve clinical outcomes for patients with Recurrent Implantation Failure: Study - Medical Dialogues

Comprehensive individualised interventions may improve clinical outcomes for patients with Recurrent Implantation Failure: Study Medical Dialogues

Published: April 10, 2025, 2:45 p.m.
Role of miRNA polymorphisms on male and female infertility and recurrent implantation failure.

MiRNAs regulate gene expression, impacting reproductive health, such as infertility and implantation failure. This study investigated the association between miRNA polymorphisms and male infertility (azoospermia, oligospermia), female infertility (endometriosis), and …

Published: April 4, 2025, midnight
A Noninvasive Menstrual Blood-Based Diagnostic Platform for Endometriosis Using Digital Droplet Enzyme-Linked Immunosorbent Assay and Single-Cell RNA Sequencing.

Endometriosis is marked by the ectopic growth, spread, and invasion of endometrial tissue beyond the uterus, resulting in recurrent bleeding, pain, reproductive challenges, and the formation of nodules or masses. …

Published: April 1, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!